{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:54:39Z","timestamp":1790045679218,"version":"4.0.1"},"reference-count":194,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T01:59:43Z","timestamp":1730944783000},"page":"395-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review"],"prefix":"10.1016","volume":"25","author":[{"given":"Varun","family":"Iyengar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-5883","authenticated-orcid":false,"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010","volume":"100","author":"Issa","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0002","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The non-Hodgkin's lymphoma classification project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.005_sbref0003","series-title":"Cancer stat facts: NHL - Diffuse large B-cell lymphoma (DLBCL)","year":"2024"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0004","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-136271","article-title":"Unmet medical need among elderly patients with previously untreated DLBCL characterized using real-world data in the United States","volume":"136","author":"Shewade","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00130404-200511000-00004","article-title":"Physiologic aspects of aging: impact on cancer management and decision making, part I","volume":"11","author":"Sawhney","year":"2005","journal-title":"Cancer J Sudbury Mass"},{"issue":"7 Suppl","key":"10.1016\/j.clml.2024.11.005_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/1097-0142(19941001)74:7+<1995::AID-CNCR2820741702>3.0.CO;2-Y","article-title":"Cancer in older persons. Magnitude of the problem\u2013how do we apply what we know?","volume":"74","author":"Yancik","year":"1994","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0008","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","article-title":"Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma","volume":"119","author":"Klapper","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0009","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2024.11.005_bib0011","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.11.005_bib0012","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0013","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","article-title":"Analysis of very elderly (\u226580 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome","volume":"156","author":"Nabhan","year":"2012","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.clml.2024.11.005_bib0014","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2024.11.005_bib0015","first-page":"1547","volume":"I","year":"1990"},{"issue":"14","key":"10.1016\/j.clml.2024.11.005_bib0016","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0017","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0018","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2024.11.005_bib0019","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.11.005_bib0020","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0021","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jgo.2020.02.002","article-title":"Practice patterns in older patients with diffuse large B-cell lymphoma: a medicare analysis, 2007-2015","volume":"11","author":"Levin","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.11.005_bib0022","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0023","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2024.11.005_bib0024","first-page":"86","article-title":"Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study","volume":"99","author":"Juul","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"3","key":"10.1016\/j.clml.2024.11.005_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002770000255","article-title":"Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study","volume":"80","author":"Peters","year":"2001","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0026","first-page":"605","article-title":"Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study","volume":"26","author":"Magnuson","year":"2018","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0027","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: a systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.11.005_bib0028","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1200\/OP.21.00743","article-title":"The use and knowledge of validated geriatric assessment instruments among us community oncologists","volume":"18","author":"Gajra","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"13","key":"10.1016\/j.clml.2024.11.005_bib0029","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.11.005_bib0030","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.11.005_bib0031","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.clml.2024.11.005_bib0032","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.11.005_bib0033","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0034","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.clml.2024.11.005_bib0035","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","article-title":"A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL","volume":"5","author":"Isaksen","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0036","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large b-cell lymphoma: the prospective elderly project of the fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0037","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hon.3081","article-title":"The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi","volume":"41","author":"Cencini","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.11.005_bib0038","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood-2019-123027","volume":"134","author":"Spina","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0039","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bjh.16049","article-title":"Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations","volume":"187","author":"Ong","year":"2019","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0040","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood-2023-184522","article-title":"Simplified geriatric assessment-albumin: the modified tool for older diffuse large b-cell lymphoma in China","volume":"142","author":"Yun","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0041","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jgo.2021.10.003","volume":"13","author":"Brem","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0042","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","article-title":"Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates","volume":"5","author":"Holmes","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.11.005_bib0043","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.3390\/cancers15245845","article-title":"The role of geriatric assessment in the management of diffuse large b-cell lymphoma","volume":"15","author":"Merli","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.clml.2024.11.005_bib0044","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.1996.14.7.2131","article-title":"Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study","volume":"14","author":"Kramer","year":"1996","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clml.2024.11.005_bib0045","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.clml.2024.11.005_bib0046","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase iii trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0047","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3324\/haematol.2011.057240","article-title":"Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup","volume":"97","author":"Thunberg","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0048","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","volume":"137","author":"Ollila","year":"2021","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.clml.2024.11.005_bib0049","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large b-cell lymphoma: does subtype make a difference in therapy selection?","author":"Nowakowski","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"25","key":"10.1016\/j.clml.2024.11.005_bib0050","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0051","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1474-9726.2008.00443.x","article-title":"B-cell diversity decreases in old age and is correlated with poor health status","volume":"8","author":"Gibson","year":"2009","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0052","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/clim.1999.4781","article-title":"Immunoglobulin VH gene expression in human aging","volume":"93","author":"Wang","year":"1999","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0053","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/leu.2010.302","article-title":"The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma","volume":"25","author":"Ruminy","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0054","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/sj.leu.2404370","article-title":"Novel Ig V gene features of t (14;18) and t (3;14) de novo diffuse large B-cell lymphoma displaying germinal center-B cell like and non-germinal center-B cell like markers","volume":"20","author":"Jardin","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.11.005_bib0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0056","doi-asserted-by":"crossref","first-page":"e23921","DOI":"10.1016\/j.heliyon.2023.e23921","article-title":"The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"issue":"17","key":"10.1016\/j.clml.2024.11.005_bib0057","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clml.2024.11.005_bib0058","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/bloodadvances.2021004668","article-title":"Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies","volume":"5","author":"Stengel","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0059","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3324\/haematol.2017.167619","article-title":"Unmet needs in the scientific approach to older patients with lymphoma","volume":"102","author":"Bron","year":"2017","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.clml.2024.11.005_bib0060","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0061","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0062","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0063","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10522-015-9578-8","article-title":"Inflammaging decreases adaptive and innate immune responses in mice and humans","volume":"17","author":"Frasca","year":"2016","journal-title":"Biogerontology"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0064","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-cellbio-011620-034148","article-title":"B Cell Immunosenescence","volume":"36","author":"Frasca","year":"2020","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0066","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov"},{"issue":"26","key":"10.1016\/j.clml.2024.11.005_bib0067","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1038\/sj.onc.1206651","article-title":"Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples","volume":"22","author":"Waki","year":"2003","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0068","doi-asserted-by":"crossref","first-page":"2401S","DOI":"10.1093\/jn\/132.8.2401S","article-title":"Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer","volume":"132","author":"Richardson","year":"2002","journal-title":"J Nutr"},{"issue":"7277","key":"10.1016\/j.clml.2024.11.005_bib0069","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0071","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2021-149019","article-title":"Efficacy of Ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed diffuse large B cell lymphoma: primary analysis of the australasian leukaemia & lymphoma group NHL29 study","volume":"138","author":"Verner","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0072","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B -cell-like subtype diffuse large B -cell lymphoma is dependent upon IRF 4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0073","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0074","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1182\/blood-2023-179200","article-title":"A randomized, open-label, phase 3 study of acalabrutinib in combination with rituximab and reduced dose CHOP (R-miniCHOP) in older adults with untreated diffuse large b-cell lymphoma (ARCHED \/GLA 2022-1)","volume":"142","author":"Christofyllakis","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0075","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1182\/blood-2023-186591","article-title":"The ZR2-minichop Study:zanubrutinib, lenalidomide, rituximab, cyclophosphamide, vincristine, epirubicin and prednisone in elderly patients with previously untreated diffuse large B-cell lymphoma","volume":"142","author":"Sun","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.11.005_bib0076","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0077","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1182\/blood-2023-181349","article-title":"Risks and outcomes of tumor lysis syndrome in patients admitted with diffuse large b cell lymphoma: a nationwide analysis","volume":"142","author":"Farooq","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0078","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1756-8722-5-75","article-title":"Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies","volume":"5","author":"McBride","year":"2012","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0079","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.11.005_bib0080","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0081","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/ejh.13068","article-title":"Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma","volume":"100","author":"Lakshmaiah","year":"2018","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0082","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","article-title":"Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim","volume":"12","author":"Balducci","year":"2007","journal-title":"The Oncologist"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0083","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3324\/haematol.2021.278719","article-title":"Prephase rituximab\/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma","volume":"107","author":"Lin","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0084","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"issue":"28","key":"10.1016\/j.clml.2024.11.005_bib0085","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0086","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN Guidelines insights: hematopoietic growth factors, version 1.2020","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0087","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","article-title":"Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large b-cell lymphoma","volume":"14","author":"Olszewski","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0088","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large b-cell lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.11.005_bib0089","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0091","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0092","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large b-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.11.005_bib0093","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/bloodadvances.2016002675","article-title":"Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study","volume":"1","author":"Giri","year":"2017","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.clml.2024.11.005_bib0094","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.11.005_bib0095","first-page":"1839","article-title":"Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study","volume":"1","author":"Dinmohamed","year":"2017","journal-title":"1989 to 2015. Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0096","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9880","key":"10.1016\/j.clml.2024.11.005_bib0097","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0098","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.18341","article-title":"The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma","volume":"199","author":"Kawasaki","year":"2022","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.11.005_bib0099","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2023.41.16_suppl.7518","article-title":"Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study","volume":"41","author":"Hu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.11.005_bib0100","article-title":"Point and counterpoint: polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma","volume":"12","author":"Thomas","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0101","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0102","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0103","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0104","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4143\/crt.2020.626","article-title":"Prognostic impact of age at the time of diagnosis in korean patients with diffuse large b-cell lymphoma in the rituximab era: a single institution study","volume":"53","author":"Hwang","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/joim.12889","article-title":"Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age","volume":"285","author":"Eyre","year":"2019","journal-title":"J Intern Med"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0106","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0107","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41416-021-01525-4","article-title":"Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England","volume":"126","author":"Hounsome","year":"2022","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.clml.2024.11.005_bib0108","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1093\/annonc\/mdt282","article-title":"Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA","volume":"24","author":"Trebouet","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.11.005_bib0109","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/0284186X.2015.1115124","article-title":"Trends in hematological cancer in the elderly in Denmark, 1980-2012","volume":"55","author":"Ocias","year":"2016","journal-title":"Acta Oncol Stockh Swed"},{"issue":"19","key":"10.1016\/j.clml.2024.11.005_bib0110","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Cardiac risk factors, and cardiac toxicity in elderly patients with diffuse b-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0111","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clml.2024.11.005_bib0112","unstructured":"Pfizer. Doxorubicin hydrochloride [package insert]. U.S. food and drug administration. [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050467s078,050629s030lbl.pdf]. Revised March 2020. Accessed May 20, 2024."},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0114","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cam4.3730","article-title":"R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients \u226560 years: results of a randomized phase 2 study from the Spanish GELTAMO group","volume":"10","author":"Sancho","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hon.2764","article-title":"Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity","volume":"38","author":"Rigacci","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2024.11.005_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103377","article-title":"Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: a systematic review and single-arm metanalysis","volume":"163","author":"Visco","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0117","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0119","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3109\/10428194.2015.1096356","article-title":"Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria","volume":"57","author":"Rashidi","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jgo.2019.06.020","article-title":"Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi","volume":"11","author":"Merli","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"S3","key":"10.1016\/j.clml.2024.11.005_bib0121","doi-asserted-by":"crossref","first-page":"e91359ec","DOI":"10.1097\/01.HS9.0000967820.91359.ec","article-title":"S227: initial safety data from the phase 3 polar bear trial in elderly or frail patients with diffuse large cell lymphoma, comparing r-pola-mini-chp and r-mini-chop","volume":"7","author":"Jerkeman","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0123","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.11.005_bib0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/2.suppl_1.57","article-title":"PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)","volume":"2","author":"Philip","year":"1991","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.11.005_bib0126","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2024.11.005_bib0127","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0128","first-page":"793","article-title":"High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an \u201cIntergruppo Italiano Linfomi\u201d randomized trial","volume":"90","author":"Vitolo","year":"2005","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0129","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","article-title":"Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study","volume":"18","author":"Chiappella","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11912-015-0465-x","article-title":"High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma","volume":"17","author":"Lahoud","year":"2015","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","article-title":"Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity","volume":"87","author":"Elstrom","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.11.005_bib0132","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/annonc\/mdw653","article-title":"Treatment outcomes for older patients with relapsed\/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial","volume":"28","author":"Davison","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0133","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","article-title":"High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study","volume":"20","author":"Chihara","year":"2014","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0134","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.jtct.2022.05.029","article-title":"Outcomes of autologous hematopoietic cell transplantation in older patients with diffuse large B-cell lymphoma","volume":"28","author":"Munshi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0135","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (\u226560 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0136","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/bmt.2010.289","article-title":"Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over","volume":"46","author":"Andorsky","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0137","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0138","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.11.005_bib0139","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.11.005_bib0140","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.11.005_bib0142","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clml.2024.11.005_bib0143","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.11.005_bib0144","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0145","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0146","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of Axicabtagene Ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0147","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients \u2013a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2021","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.clml.2024.11.005_bib0148","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1080\/10428194.2022.2113526","article-title":"Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma","volume":"63","author":"Oluwole","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.clml.2024.11.005_bib0149","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.11.005_bib0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejca.2022.08.019","article-title":"Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population","volume":"175","author":"Vic","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0151","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41409-019-0654-6","article-title":"Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies","volume":"55","author":"Lin","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.11.005_bib0152","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2020.38.15_suppl.8039","article-title":"Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy","volume":"38","author":"Fitzgerald","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.11.005_bib0153","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2024.11.005_bib0154","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","article-title":"Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study","volume":"57","author":"Arcari","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0156","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2024.11.005_bib0157","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.11.005_bib0158","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.11.005_bib0159","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.clml.2024.11.005_bib0160","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0161","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2023-174497","article-title":"Effectiveness of chemo-immunotherapy (CIT) and novel therapies in second or later line of therapy (2L+) for patients with relapsed\/refractory (R\/R) aggressive large B-cell lymphoma (LBCL)","volume":"142","author":"Nastoupil","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0162","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2023-173143","article-title":"Tafasitamab for the treatment of relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) in the US real-world setting","volume":"142","author":"Saverno","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0163","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood-2023-185992","article-title":"Tafasitamab and lenalidomide in relapsed\/refractory B-cell lymphoma: a multicenter retrospective real-world-study of patients from Germany and Austria","volume":"142","author":"Ruckdeschel","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0164","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/blood-2023-174257","article-title":"Loncastuximab in high-risk and heavily-pretreated relapsed\/refractory diffuse large B-cell lymphoma: a real world analysis from 21 US centers","volume":"142","author":"Ayers","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0166","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1182\/blood-2023-173645","article-title":"Loncastuximab tesirine demonstrated substantial single-agent efficacy and manageable safety profile in heavily pretreated chinese patients with relapsed or refractory (R\/R) diffuse large b-cell lymphoma (DLBCL)","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.11.005_bib0167","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2019-124886","article-title":"Mechanistic characterization of tafasitamab-mediated antibody-dependent cellular phagocytosis alone or in combination with lenalidomide","volume":"134","author":"Mougiakakos","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.11.005_bib0168","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0169","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell\u2013engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.11.005_bib0170","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.11.005_bib0171","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0172","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of b-cell non-Hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0173","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2022-156125","article-title":"innate cell engager afm13 combined with preactivated and expanded cord blood-derived NK cells for patients with double refractory CD30+ lymphoma","volume":"140","author":"Nieto","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0174","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2021-148607","article-title":"Phase 1 dose escalation and cohort expansion study of the anti-ROR1 antibody-drug conjugate zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0175","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2021-150606","article-title":"Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non-Hodgkin's lymphoma: initial clinical results","volume":"138","author":"Mehta","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0176","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2021-153683","article-title":"CD47-Blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2024.11.005_bib0177","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.11.005_bib0178","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","article-title":"The senescence-associated secretory phenotype and its physiological and pathological implications","volume":"25","author":"Wang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2024.11.005_bib0179","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.clml.2024.11.005_bib0180","doi-asserted-by":"crossref","first-page":"e75374","DOI":"10.7554\/eLife.75374","article-title":"Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study","volume":"11","author":"Morales Berstein","year":"2022","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0181","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","article-title":"Geriatric assessment in older adults with non-Hodgkin lymphoma: a Young International Society of Geriatric Oncology (YSIOG) review paper","volume":"13","author":"Akhtar","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2024.11.005_bib0182","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/01.HS9.0000851416.21855.57","article-title":"PB2146: a phase 2, open-label study of loncastuximab tesirine in combination with rituximab (LONCA-r) in previously untreated unfit\/frail patients with diffuse large b-cell lymphoma (DLBCL) (lotis-9)","volume":"6","author":"Westin","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0183","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2023-188854","volume":"142","author":"Melchardt","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0184","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.11.005_bib0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0186","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2023-180246","article-title":"Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with relapsed\/refractory diffuse large B-Cell lymphoma ineligible for autologous stem cell transplant: updated results from epcore NHL-2","volume":"142","author":"Brody","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.11.005_bib0187","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1200\/JCO.2024.42.16_suppl.7037","article-title":"Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: updated results from EPCORE NHL-2","volume":"42","author":"Brody","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0188","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2023-180089","article-title":"Subcutaneous Epcoritamab plus lenalidomide in patients with relapsed\/refractory diffuse large B-cell lymphoma from EPCORE NHL-5","volume":"142","author":"Avivi","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0189","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1182\/blood-2023-174213","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2024.11.005_bib0190","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination targeted therapy in relapsed diffuse large B-cell lymphoma","volume":"390","author":"Melani","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.11.005_bib0191","author":"Abramson","year":"2024"},{"issue":"5","key":"10.1016\/j.clml.2024.11.005_bib0192","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/jgs.18267","article-title":"Development and implementation of an interdisciplinary telemedicine clinic for older patients with cancer\u2014preliminary data","volume":"71","author":"Alexander","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.005_bib0193","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2023-188143","article-title":"Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: a prospective geriatric assessment (GA) study","volume":"142","author":"Torka","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.11.005_bib0194","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:26:14Z","timestamp":1747686374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":194,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265024024054"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}